Maravai LifeSciences Reports Second Quarter 2026 Financial Results
Maravai LifeSciences reported Q2 2026 revenue of $51.4 million, up 8.5% year-over-year, with Adjusted EBITDA turning positive to $8.7 million compared to a loss in the prior year. The company raised its full-year 2026 Adjusted EBITDA guidance to a range of $33 million to $35 million, up from the previous range of $30 million to $32 million, while reiterating its revenue guidance of $205 million to $215 million.
Key figures
- Revenue
- 51442000
- Guidance
- FY26 revenue $205.0M-$215.0M (reiterated); FY26 Adjusted EBITDA $33.0M-$35.0M (raised from $30.0M-$32.0M)
- Revenue Yoy
- 8.5%
- Cygnus revenue
- 16773000
- Adjusted ebitda
- 8700000
- Trilink revenue
- 34669000
- Cygnus revenue yoy
- 2.8%
- Trilink revenue yoy
- 11.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.